Proactive Investors - Run By Investors For Investors

Avacta Group CEO Alastair Smith confident of licensing deals this year

Alastair Smith, chief executive of Avacta Group Plc (LON:AVCT), tells Proactive's Andrew Scott they've been making significant progress on partnering discussions and he's expecting to deliver at least one substantial licensing deal before its Affimer technology reaches the clinic.

Smith adds that multiple potential pharma and biotech partners are interested in Avacta’s technology.

 
Meet Alliance Pharma PLC, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »
View full AVCT profile View Profile

Avacta Group PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use